Bionomics Australian S.E.

Equities

BNO

AU000000BNO5

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 02:10:06 2023-08-24 am EDT			5-day change	1st Jan Change
0.01 ^AUD	-.--%		-.--%	-.--%

Mar. 21	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	CI
Mar. 15	Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Bionomics Limited Reports Earnings Results for the Full Year Ended June 30, 2021

August 25, 2021 at 01:53 am EDT

Bionomics Limited announced earnings results for the full year ended June 30, 2021. For the full year, the company announced sales was AUD 0 compared to AUD 46,662 a year ago. Net loss was AUD 8.697 million compared to AUD 7.118 million a year ago. Basic loss per share was AUD 0.01 compared to AUD 0.01 a year ago.

Latest news about Bionomics

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	Mar. 21	CI
Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 15	CI
Wall Street Set to Open Higher in Monday Trading Ahead of Economic Indicators Data	Jan. 22	MT
US Futures Poised to Open Week Higher, Leading Economic Indicators on Tap	Jan. 22	MT
Bionomics Limited Announces Retirement of Dr. Errol De Souza as Board of Directors, Effective November 30, 2023	Nov. 28	CI
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2%	Nov. 10	DJ
Bionomics to Advance Social Anxiety Disorder Treatment Into Phase 3 Studies After End-of-Phase 2 Meeting With US FDA	23-10-16	MT
Bionomics Limited Announces Successful and Favorable Outcomes of an End-Of-Phase 2 Meeting Meeting with the U.S. Food and Drug Administration	23-10-16	CI
Bionomics Trades 1.8% Lower in Premarket Activity Tuesday After Surging 46% in Previous Regular Trading Session	23-10-03	MT
Top Premarket Gainers	23-10-02	MT
Bionomics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-29	CI
Bionomics Retreats 15% Premarket Friday After Surging 244% in Previous Trading Session Following Positive Phase 2b Data	23-09-29	MT
Bionomics Sinks 12% After Hours Thursday Following 244% Surge in Previous Regular Trading Session on Positive Phase 2b Trial Results	23-09-28	MT
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	23-09-28	MT
Top Midday Gainers	23-09-28	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-09-28	MT
Sector Update: Health Care	23-09-28	MT
Biometrics Soar After Company Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms	23-09-28	MT
Wall Street Set to Open Flat; Q2 GDP Rises 2.1%; Jobless Claims Lower Than Expected	23-09-28	MT
Sector Update: Health Care Stocks Gain Premarket Thursday	23-09-28	MT
Sector Update: Health Care	23-09-28	MT
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket	23-09-28	MT
Bionomics Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms	23-09-28	MT
Top Premarket Gainers	23-09-28	MT
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	23-09-28	CI

Chart Bionomics

Duration

Period

More charts

Company Profile

Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the Î±7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its Î±7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimerâs disease and other central nervous system conditions. The Companyâs CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.

Sector

Biotechnology & Medical Research

Calendar

2024-08-20 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Bionomics

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.459 AUD

Average target price

15.3 AUD

Spread / Average Target

+948.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs